Merus (NASDAQ:MRUS) Holdings Decreased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB reduced its position in shares of Merus (NASDAQ:MRUS) by 6.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,500 shares of the biotechnology company’s stock after selling 5,000 shares during the period. Rhenman & Partners Asset Management AB owned about 0.11% of Merus worth $3,133,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Merus by 49.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,232 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 4,385 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Merus by 17.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock valued at $4,207,000 after buying an additional 12,212 shares during the last quarter. Verition Fund Management LLC raised its stake in Merus by 16.6% during the third quarter. Verition Fund Management LLC now owns 42,746 shares of the biotechnology company’s stock worth $2,136,000 after acquiring an additional 6,071 shares during the period. HighTower Advisors LLC acquired a new stake in Merus during the third quarter worth about $358,000. Finally, Wellington Management Group LLP lifted its holdings in Merus by 73.6% in the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after acquiring an additional 1,224,573 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Price Performance

MRUS opened at $38.11 on Friday. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -9.65 and a beta of 1.02. Merus has a 1-year low of $36.46 and a 1-year high of $61.61. The business has a 50 day moving average price of $44.02 and a two-hundred day moving average price of $45.77.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Equities analysts expect that Merus will post -3.85 EPS for the current fiscal year.

Analyst Ratings Changes

MRUS has been the topic of a number of research reports. William Blair reiterated an “outperform” rating on shares of Merus in a research report on Friday, February 28th. Needham & Company LLC lowered their price objective on Merus from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price on the stock. Piper Sandler assumed coverage on shares of Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target for the company. Finally, Citigroup increased their price objective on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.